Brian Armstrong, NewLimit co-founder (Stefan Wermuth/Bloomberg via Getty Images)
May 6, 2025 11:00 AM EDT
Financing

Bri­an Arm­strong’s NewLim­it rais­es a $130M Se­ries B, lay­ing out road map for an­ti-ag­ing drugs

Andrew Dunn

Senior Biopharma Correspondent

NewLim­it, an an­ti-ag­ing biotech start­up backed by Coin­base CEO Bri­an Arm­strong, has raised a $130 mil­lion Se­ries B round to get its lead drug can­di­dates …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

A new dawn for psy­che­delics? Com­pass could be the first to find out

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times